# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2211-2220 of 2224 results.
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Completed
Last Changed: Jul 01, 2014
First Received: Apr 30, 2008
Disease(s): Leukemia, Lymphoma
Intervention(s): alemtuzumab, rituximab, pentostatin, sargramostim
Locations: Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Status: Completed
Last Changed: Mar 15, 2018
First Received: Jan 23, 2012
Disease(s): Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Intervention(s): Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab, Pharmacological Study
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Status: Withdrawn
Last Changed: Sep 27, 2017
First Received: Jan 25, 2016
Disease(s): Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
Intervention(s): Ibrutinib, Idelalisib
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Status: Completed
Last Changed: May 09, 2016
First Received: Sep 30, 2010
Disease(s): B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Intervention(s): carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
Locations: Ohio State University Medical Center, Columbus, Ohio, United States
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Terminated
Last Changed: Apr 03, 2019
First Received: Aug 10, 2015
Disease(s): Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Intervention(s): Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Status: Recruiting
Last Changed: Jul 27, 2020
First Received: Jun 19, 2019
Disease(s): Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Intervention(s): Etoposide, Doxorubicin, Vincristine, Prednisone, Cyclophosphamide, Inotuzumab Ozogamicin
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Status: Recruiting
Last Changed: Oct 23, 2020
First Received: Feb 24, 2015
Disease(s): Lymphoma, Acute Lymphoblastic Leukemia
Intervention(s): Apixaban, No systemic anticoagulant prophylaxis
Locations: Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr., Phoenix, Arizona, United States
City of Hope, Duarte, California, United States
Loma Linda University Cancer Center, Loma Linda, California, United States
Childrens Hospital Of La, Los Angeles, California, United States
Local Institution, Los Angeles, California, United States
... and 114 other locations.
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Status: Unknown status
Last Changed: Mar 20, 2012
First Received: Dec 05, 2003
Disease(s): Lymphoma
Intervention(s): rituximab
Locations: Stanford University Medical Center, Stanford, California, United States
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Status: Completed
Last Changed: Jun 25, 2015
First Received: Oct 08, 2010
Disease(s): B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
Intervention(s): PCI-32765, ofatumumab
Locations: The Ohio State University, Columbus, Ohio, United States
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Status: Terminated
Last Changed: May 14, 2019
First Received: Oct 07, 2014
Disease(s): Follicular Lymphoma, Small Lymphocytic Lymphoma
Intervention(s): Idelalisib, Rituximab
Locations: Pacific Shores Medical Group, Long Beach, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
St. Agnes Hospital, Baltimore, Maryland, United States
Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
... and 2 other locations.